Media Summary: IPC Councilor, Dr. Paolo Gisondi, examines Dr. Tsoi discusses his research on the effects Ixekizumab and Guselkumab has on dermaimmunology is its ability to change its phenotype (CONVENTIAL,
Psoriasis And Beyond Targeting The Il 17 Pathway - Detailed Analysis & Overview
IPC Councilor, Dr. Paolo Gisondi, examines Dr. Tsoi discusses his research on the effects Ixekizumab and Guselkumab has on dermaimmunology is its ability to change its phenotype (CONVENTIAL, Author video for 'Signalling of multiple interleukin (IL)-17 family cytokines via
